Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment

Journal Article · Mon Jun 10 00:00:00 EDT 2024 · JAMA Neurology

DOI:https://doi.org/10.1001/jamaneurol.2024.1612· OSTI ID:2470703

Groot, Colin ^[1]; Smith, Ruben ^[2]; Collij, Lyduine E. ^[3]; Mastenbroek, Sophie E. ^[4]; Stomrud, Erik ^[5]; Binette, Alexa Pichet ^[2]; Leuzy, Antoine ^[2]; Palmqvist, Sebastian ^[5]; Mattsson-Carlgren, Niklas ^[5]; Strandberg, Olof ^[2]; Cho, Hanna ^[6]; Lyoo, Chul Hyoung ^[6]; Frisoni, Giovanni B. ^[7]; Peretti, Debora E. ^[7]; Garibotto, Valentina ^[8]; La Joie, Renaud ^[9]; Soleimani-Meigooni, David N. ^[10]; Rabinovici, Gil ^[10]; Ossenkoppele, Rik ^[11]; Hansson, Oskar ^[5]

---

1. Lund Univ. (Sweden); Vrije Univ., Amsterdam (Netherlands)
2. Lund Univ. (Sweden)
3. Lund Univ. (Sweden); Vrije Univ., Amsterdam (Netherlands); Amsterdam Univ. Medical Center (Netherlands)
4. Lund Univ. (Sweden); Amsterdam University Medical Center (Netherlands); Vrije Univ., Amsterdam (Netherlands)
5. Lund Univ. (Sweden); Skåne University Hospital (Sweden)
6. Yonsei Univ., Seoul (Korea, Republic of)
7. Univ. of Geneva (Switzerland)
8. Univ. of Geneva (Switzerland); Ecole Polytechnique Federale Lausanne (EPFL) (Switzerland). Center for Biomedical Imaging
9. Univ. of California, San Francisco, CA (United States)
10. Univ. of California, San Francisco, CA (United States); Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
11. Lund Univ. (Sweden); Vrije Univ., Amsterdam (Netherlands); Amsterdam University Medical Center (Netherlands)

An accurate prognosis is especially pertinent in mild cognitive impairment (MCI), when individuals experience considerable uncertainty about future progression. To evaluate the prognostic value of tau positron emission tomography (PET) to predict clinical progression from MCI to dementia. This was a multicenter cohort study with external validation and a mean (SD) follow-up of 2.0 (1.1) years. Data were collected from centers in South Korea, Sweden, the US, and Switzerland from June 2014 to January 2024. Participant data were retrospectively collected and inclusion criteria were a baseline clinical diagnosis of MCI; longitudinal clinical follow-up; a Mini-Mental State Examination (MMSE) score greater than 22; and available tau PET, amyloid-β (Aβ) PET, and magnetic resonance imaging (MRI) scan less than 1 year from diagnosis. A total of 448 eligible individuals with MCI were included (331 in the discovery cohort and 117 in the validation cohort). None of these participants were excluded over the course of the study. Exposures included Tau PET, Aβ PET, and MRI. Positive results on tau PET (temporal meta–region of interest), Aβ PET (global; expressed in the standardized metric Centiloids), and MRI (Alzheimer disease [AD] signature region) was assessed using quantitative thresholds and visual reads. Clinical progression from MCI to all-cause dementia (regardless of suspected etiology) or to AD dementia (AD as suspected etiology) served as the primary outcomes. The primary analyses were receiver operating characteristics. In the discovery cohort, the mean (SD) age was 70.9 (8.5) years, 191 (58%) were male, the mean (SD) MMSE score was 27.1 (1.9), and 110 individuals with MCI (33%) converted to dementia (71 to AD dementia). Only the model with tau PET predicted all-cause dementia (area under the receiver operating characteristic curve [AUC], 0.75; 95% CI, 0.70-0.80) better than a base model including age, sex, education, and MMSE score (AUC, 0.71; 95% CI, 0.65-0.77; P = .02), while the models assessing the other neuroimaging markers did not improve prediction. In the validation cohort, tau PET replicated in predicting all-cause dementia. Compared to the base model (AUC, 0.75; 95% CI, 0.69-0.82), prediction of AD dementia in the discovery cohort was significantly improved by including tau PET (AUC, 0.84; 95% CI, 0.79-0.89; P < .001), tau PET visual read (AUC, 0.83; 95% CI, 0.78-0.88; P = .001), and Aβ PET Centiloids (AUC, 0.83; 95% CI, 0.78-0.88; P = .03). In the validation cohort, only the tau PET and the tau PET visual reads replicated in predicting AD dementia. In this study, tau-PET showed the best performance as a stand-alone marker to predict progression to dementia among individuals with MCI. This suggests that, for prognostic purposes in MCI, a tau PET scan may be the best currently available neuroimaging marker.

• Research Organization: Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
• Sponsoring Organization: USDOE
• Grant/Contract Number: AC02-05CH11231
• OSTI ID: 2470703
• Journal Information: JAMA Neurology, Journal Name: JAMA Neurology Journal Issue: 8 Vol. 81; ISSN 2168-6149
• Publisher: American Medical Association
• Country of Publication: United States
• Language: English

Related Subjects

59 BASIC BIOLOGICAL SCIENCES
Neurosciences &amp; Neurology